Gritstone bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gritstone bio, Inc.
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
- Artificial Intelligence
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Gritstone Oncology, Inc.